Kinerja Keuangan Perusahaan Farmasi BUMN dan Non-BUMN Sebelum dan Selama Pandemi - Michelia Yemima Hardwi Atmaja; Arthik Davianti (Owner : Riset dan Jurnal Akuntansi, 2022)
Since the emergence of COVID-19 in Indonesia, several corporate sectors in Indonesia have had their operational activities disrupted, which has caused a decline in revenue. However, there are industrial sectors that have benefited from the COVID-19 pandemic. One of them is the pharmaceutical industry. This study aims to determine the financial performance of public and private pharmaceutical companies before and during the pandemic. This research is descriptive quantitative research with the data source being secondary data. The data analysis technique uses net profit margin and returns on equity as profitability ratio, current ratio and quick ratio as liquidity ratio, total asset turnover and inventory turnover as activity ratio, debt to equity ratio, and debt to asset ratio as solvency ratios. The results show that private companies have better financial performance than public companies. Sido Muncul company has the best liquidity and solvency performance among other companies. Merck Indonesia has the best profitability performance, while Pyridam Farma has the best activity performance. In contrast, Indofarma has the worst performance among others even though in terms of activity performance, Indofarma is the most efficient company in selling products. Sejak kemunculan COVID-19 di Indonesia, beberapa sektor perusahaan di Indonesia terganggu aktivitas operasionalnya yang menyebabkan penurunan pendapatan. Namun, terdapat sektor industri yang diuntungan dari adanya pandemi COVID-19. Salah satunya industri farmasi. Penelitian bertujuan untuk mengetahui kinerja keuangan perusahaan farmasi BUMN dan Non-BUMN sebelum dan selama pandemi. Penelitian ini merupakan penelitian kuantitatif deskriptif dengan sumber data yang digunakan berupa data sekunder. Teknik analisis data menggunakan analisis rasio profitabilitas yaitu net profit margin dan return on equity, rasio likuiditas yaitu current ratio dan quick ratio, rasio aktivitas yaitu total asset turnover dan inventory turnover, dan rasio solvabilitas yaitu debt to equity ratio dan debt to asset ratio. Hasil penelitian menunjukkan bahwa perusahaan Non-BUMN memiliki kinerja keuangan perusahaan yang lebih baik dari perusahaan BUMN. Hal ini dapat dilihat bahwa perusahaan Sido Muncul memiliki kinerja likuiditas dan solvabilitas paling baik diantara perusahaan lainnya. Kinerja profitabilitas paling baik dimiliki oleh perusahaan Merck Indonesia sedangkan Pyridam Farma memiliki kinerja aktivitas terbaik diantara lainnya. Sementara Indofarma memiliki kinerja paling buruk diantara lainnya meskipun pada kinerja aktivitas, Indofarma merupakan perusahaan yang paling efisien dalam menjual produknya.